PPT - US Food and Drug Administration Home Page
Benefits and Risks of GnRH/LHRH Agonists and Antagonists in Advanced Prostate Cancer Patients John Trachtenberg, MD Director, Prostate Cancer Princess.
Pembrolizumab in advanced melanoma
ASCO 2015 Lymphoma update
Wei Ai, M.D., Ph.D. June 2012. I. Lymphoma: bendamustine II. CLL/SLL: Btk inhibitor III. Pre-B ALL: Bite biphasic antibody IV. Multiple Myeloma: Carfilzomib.
ASCO REVIEW 2011 T Martin, MD ASCO, Lugano, IMF-Paris Highlights May - June, 2011
M. Ychou 1 , F. Desseigne 2 , R. Guimbaud 3 , M. Ducreux 4 , O. Bouché 5 ,
Malignant Melanoma
Benefits and Risks of GnRH/LHRH Agonists and Antagonists in Advanced Prostate Cancer Patients
NEW AGENTS ON THE HORIZON: IMPLICATIONS FOR PHASE I, II & III TRIALS DNA Repair and PARP inhibitors Carol Aghajanian, Nicoletta Colombo & Amit Oza Acknowledgements:
RANDOMIZED PHASE II TRIAL COMPARING FOLFIRINOX (5FU/LEUCOVORIN, IRINOTECAN AND OXALIPLATIN) VS GEMCITABINE AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC.